Medical Therapy Affects the Arteriopathy of Vascular Ehlers-Danlos Syndrome

Abstract

Listen

Translate article

Identification of the underlying genetic causes of single gene disorders of the arteries has led to improved understanding of the aberrant signalling pathways involved and is producing disease-specific medical therapies beyond simple control of blood pressure and heart rate. Here, Baderkhan et al. report their experience with celiprolol treatment in 40 patients with mutations in the gene COL3A1 causing vascular Ehlers-Danlos Syndrome (vEDS). The dose of celiprolol was up-titrated every six months to reach 400 mg daily, and was well tolerated.